Patent for BrainStorm’s technology for Parkinson’s

BrainStorm Cell Therapeutics, a developer of adult stem cell therapeutics for neurodegenerative diseases, said it received notice of allowance from the US Patent Office for a patent application titled “Isolated cells and populations comprising same for the treatment of CNS diseases.”

BrainStorm said the patent is the result of the ongoing development of its NurOwn technology.

“The allowed claims cover methods of treating amyotrophic lateral sclerosis (ALS) and Parkinson’s disease using mesenchymal stem cells that secrete neurotrophic factors, including glial derived neurotrophic factor (GDNF),” said BrainStorm.

BrainStorm CEO Chaim Lebovits said: “We continue to protect our technology through strategic intellectual property achievements and this notice of allowance from the USPTO is a welcome addition to our IP portfolio.”